EKF Diagnostics Holdings PLC Total Voting Rights (4268X)

TIDMEKF

RNS Number : 4268X

EKF Diagnostics Holdings PLC

25 April 2023

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Total Voting Rights

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, refers to its announcement dated 23 March 2023 regarding the disposal of Advanced Diagnostic Laboratory LLC ("ADL Health") (the "Disposal").

Part of the consideration for ADL Health comprised the return of 1,200,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") which had originally been issued as part of the payment made to the vendors of ADL Health when it was acquired by EKF in 2021. The Company now confirms that these 1,200,000 Ordinary Shares have now been received by EKF and are being held in treasury.

As a result, the Company's total issued share capital now consists of 454,930,564 Ordinary Shares with one voting right per share. The Company holds 1,200,000 Ordinary Shares in treasury. The total number of voting rights in the Company is therefore 453,730,564.

The above figure of 453,730,564 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 
EKF Diagnostics Holdings plc                                  www.ekfdiagnostics.com 
Julian Baines, Executive Chair / Marc                       Tel: +44 (0)29 2071 0570 
 Davies, CFO 
 
Singer Capital Markets (Nominated Adviser &                 Tel: +44 (0)20 7496 3000 
 Broker) 
Aubrey Powell / George Tzimas / Oliver 
 Platts 
 
Walbrook PR Limited                   Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com 
Paul McManus / Lianne Applegarth          Mob: +44 (0)7980 541 893 / +44 (0)7584 391 
                                                                                 303

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is an AIM-listed global diagnostics business focussed on:

-- Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges

-- Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications, as well as other higher value Contract Manufacturing services

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREASLSAEDDEFA

(END) Dow Jones Newswires

April 25, 2023 11:10 ET (15:10 GMT)

EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024